Arrive AI selects Synoptek as a Strategic IT Partner to Power Global Expansion
With a recent injection of up to $40 million in funding from Streeterville Capital, Arrive AI is entering a critical growth phase. The company is preparing to launch its patented, autonomous delivery platform later this summer and expects to triple its staff size.
"Synoptek's strategic approach, deep expertise, robust tech stack and strong partnerships with Microsoft and ServiceNow made it a clear choice," said Mark Hamm, COO of Arrive AI. "We were searching for a partner who could move at our pace and help us build a resilient IT foundation for global expansion. After conducting an exhaustive search, we knew Synoptek would be the partner we were looking for to provide all of IT capabilities we need to take our business to the next level"
Under the three-year agreement, Synoptek will contribute to the solution definition, implementation and IT management, including, cybersecurity, enterprise-grade IT and 24/7 AI-enabled managed services operations. This engagement deepens Synoptek's presence in the high-growth logistics and manufacturing sector and aligns with its mission to deliver smart, secure and connected IT environments.
"We're proud to serve as an extension of the Arrive AI team," said Salil Godika, CEO at Synoptek. "Together, we are building a resilient and secure IT backbone that supports innovation and scale. We deliver focused solutions that incorporate exceptional customer experiences, digital application engineering, and agile infrastructure. We are committed to providing Arrive AI with the technology foundation it needs to grow with confidence."
Synoptek will provide advisory services and information sharing around security, AI and application innovation as Arrive AI continues to push boundaries in the AI transportation and logistics space.
-30-
About Arrive AI: Arrive AI's patented Autonomous Last Mile (ALM) platform enables secure, efficient delivery to and from a smart, AI-powered mailbox, whether by drone, ground robot or human courier. The platform provides real-time tracking, smart logistics alerts and advanced chain of custody controls to support shippers, delivery services and autonomous networks. By combining artificial intelligence with autonomous technology, Arrive AI makes the exchange of goods between people, robots and drones frictionless and convenient. Its system integrates with smart home devices such as doorbells, lighting and security systems to streamline the entire last-mile delivery experience. Learn more at www.arriveai.com.
Media contact: Cheryl Reed at media@arriveai.com
Investor Relations Contact: Alliance Advisors IR at ARAI.IR@allianceadvisors.com
About Synoptek: Synoptek is a global, full-service business and digital technology solutions provider and advisory firm that helps companies envision, transform, and evolve their customer experiences, application ecosystems, and infrastructures. As a systems integrator and managed technology provider, Synoptek partners with organizations worldwide, helping them navigate the ever-changing technology landscape and build solid tech foundations for their businesses.
With its comprehensive offerings, global workforce, and strategic technology partnerships, Synoptek helps companies optimize their IT environments and enable innovation through technology. With growth, ownership, inclusiveness, and philanthropy embedded in its DNA, Synoptek is committed to delivering improved business results and unmatched service to all its stakeholders.
Cautionary Note Regarding Forward Looking Statements
This news release and statements of Arrive AI's management in connection with this news release or related events contain or may contain "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements (including statements related to the closing, and the anticipated benefits to the Company, of the private placement described herein) related to future events, which may impact our expected future business and financial performance, and often contain words such as "expects", "anticipates", "intends", "plans", "believes", "potential", "will", "should", "could", "would", "optimistic" or "may" and other words of similar meaning. These forward-looking statements are based on information available to us as of the date of this news release and represent management's current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors which may be beyond our control. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. Potential investors should review Arrive AI's Registration Statement for more complete information, including the risk factors that may affect future results, which are available for review at www.sec.gov. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.
SOURCE: Arrive AI Inc.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
a day ago
- Miami Herald
Optex Systems Holdings, Inc. Announces Financial Highlights for the Three and Nine Months Ended June 29, 2025
RICHARDSON, TX / ACCESS Newswire / August 12, 2025 / Optex Systems Holdings, Inc. (Nasdaq:OPXS), a leading manufacturer of precision optical sighting systems for domestic and worldwide military and commercial applications, announced financial results for the three and nine months ended June 29, 2025. Danny Schoening, CEO of Optex Systems Holdings, Inc., commented, "We are proud to announce another record-breaking quarter for revenue, a testament to our unwavering commitment to excellence, reliability, and customer support. This milestone reflects not only our strong operational performance but also the momentum we are building across the business. "In addition to surpassing previous revenue records, we are excited to report several significant new program wins that expand our footprint in both domestic and international markets. These new awards are the result of our consistent delivery of high-quality products and the trust we have earned as a dependable defense manufacturing partner. "Our factory performance continues to highlight the strength of our team and the efficiency of our processes. As we celebrate this achievement, we remain focused on sustaining this growth trajectory, investing in innovation, and delivering superior value to our customers and shareholders. "We thank our employees, customers, and investors for their ongoing support in making this success possible." Backlog as of June 29, 2025 was $38.3 million, compared to a backlog of $45.6 million as of June 30, 2024, representing a decrease of $7.3 million, or 16.0% from the prior year June period. Subsequent to the period ended June 29, 2025, the Company announced several new awards including a $2.8 million order for the XM30 program, a $10.2 million five-year requirement-type contract award for optical sighting systems, and a $1.6 million order for laser filters, bringing our total backlog to $45.0 million as of August 5, 2025. For the three months ended June 29, 2025, our total revenue increased by $2.1 million, or 22.6%, compared to the prior year period. For the nine months ended June 29, 2025, our total revenue increased by $5.5 million, or 22.3%, compared to the prior year period. The increase in revenue was primarily driven by higher periscope production levels at the Optex Richardson segment, combined with increased customer demand across both the Optex Richardson and the Applied Optics operating segments. Consolidated gross profit for the three months ended June 29, 2025 increased by $0.3 million, or 10.0%, compared to the prior year period. Consolidated gross profit for the nine months ended June 29, 2025 increased by $1.5 million, or 21.6%, compared to the prior year period. The increase in the most recent three and nine-month period gross profit was primarily attributable to increased revenue and changes in product mix. Our operating income for the three months ended June 29, 2025 increased by $0.3 million, or 18.3%, compared to the prior year period. Our operating income for the nine months ended June 29, 2025 increased by $1.5 million, or 43.8%, compared to the prior year period. The increase in operating income was primarily driven by higher revenue and gross profit. As of June 29, 2025, Optex Systems Holdings had working capital of $19.4 million, as compared to $15.1 million as of September 29, 2024. During the nine months ended June 29, 2025, we generated operating cash of $5.4 million, primarily driven by increased net income, reductions in inventory and increased accounts payable. During the nine months ended June 29, 2025, we paid $1.0 million against the credit facility and purchased capital assets of $0.5 million. At June 29, 2025, the Company had approximately $4.9 million in cash and no draws against its revolving credit line. As of June 29, 2025, our outstanding accounts receivable balance was $4.1 million to be collected during the fourth quarter of fiscal 2025. Our key performance measures for the three and nine months ended June 29, 2025 and June 30, 2024 are summarized below. The table below summarizes our three- and nine-month operating results for the periods ended June 29, 2025 and June 30, 2024, in terms of both the GAAP net income measure and the non-GAAP Adjusted EBITDA measure. We believe that including both measures allows the reader better to evaluate our overall performance. Adjusted EBITDA has limitations and should not be considered in isolation or a substitute for performance measures calculated under GAAP. This non-GAAP measure excludes certain cash expenses that we are obligated to make. In addition, other companies in our industry may calculate Adjusted EBITDA differently than we do or may not calculate it at all, which limits the usefulness of Adjusted EBITDA as a comparative measure. Our net income increased by $0.2 million to $1.5 million for the three months ended June 29, 2025, as compared to net income of $1.3 million for the prior year period. Our adjusted EBITDA increased by $0.3 million to $2.1 million for the three months ended June 29, 2025, as compared to adjusted EBITDA of $1.8 million for the prior year period. Our net income increased by $1.3 million to $4.1 million for the nine months ended June 29, 2025, as compared to net income of $2.8 million for the prior year period. Our adjusted EBITDA increased by $1.5 million to $5.7 million for the nine months ended June 29, 2025, as compared to adjusted EBITDA of $4.2 million for the prior year period. The increase in net income and adjusted EBITDA for the most recent three and nine-month periods compared to the prior year periods is primarily driven by increased revenue and gross profit. We currently do not anticipate any significant material risks as a result of the recent tariff uncertainties or China's stranglehold on rare earths. Our defense products are primarily sourced domestically, but those which are imported are generally not subject to tariff or duties. We produce some commercial optical assemblies with selective components sourced from Taiwan; however, our current customer backlog is covered with existing material in inventory. We anticipate any future orders for these commercial products will be subject to revised pricing inclusive of any potential tariff impact. Highlights of the Consolidated and Segment Results of Operations have been prepared in accordance with GAAP. These financial highlights do not include all information and disclosures required in the consolidated financial statements and footnotes and should be read in conjunction with our Quarterly Report on Form 10Q for the three and nine months ended June 29, 2025 filed with the SEC on August 12, 2025. Optex Systems Holdings, Consolidated Balance Sheets The accompanying notes in our Quarterly Report on Form 10Q for the three and nine months ended June 29, 2025 filed with the SEC on August 12, 2025 are an integral part of these financial statements. Optex Systems Holdings, Consolidated Statements of Operations(Unaudited) The accompanying notes in our Quarterly Report on Form 10Q for the three and nine months ended June 29, 2025 filed with the SEC on August 12, 2025 are an integral part of these financial statements. ABOUT OPTEX SYSTEMS Optex, which was founded in 1987, is a Richardson, Texas based ISO 9001:2015 certified concern, which manufactures optical sighting systems and assemblies, primarily for Department of Defense (DOD) applications. Its products are installed on various types of U.S. military land vehicles, such as the Abrams and Bradley fighting vehicles, Light Armored and Armored Security Vehicles, and have been selected for installation on the Stryker family of vehicles. Optex also manufactures and delivers numerous periscope configurations, rifle and surveillance sights, and night vision optical assemblies. Optex delivers its products both directly to the military services and to prime contractors. For additional information, please visit the Company's website at Safe Harbor Statement This press release contains certain forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995, including those relating to the products and services described herein. You can identify these statements by the use of the words "may," "will," "could," "should," "would," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," "likely," "forecast," "probable," and similar expressions. These forward-looking statements represent our expectations, beliefs, intentions or strategies concerning future events, including, but not limited to, any statements regarding growth strategy; product and development programs; financial performance and financial condition (including revenue, net income, profit margins and working capital); customer demand; orders and backlog; expected timing of contract deliveries to customers and corresponding revenue recognition; increases in the cost of materials and labor; costs remaining to fulfill contracts; contract loss reserves; labor shortages; follow-on orders; supply chain challenges; the continuation of historical trends; the sufficiency of our cash balances for future liquidity and capital resource needs; the expected impact of changes in accounting policies on our results of operations, financial condition or cash flows; anticipated problems and our plans for future operations; and the economy in general or the future of the defense industry. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. Such risks and uncertainties include, but are not limited to, continued funding of defense programs and military spending, the timing of such funding, general economic and business conditions, including unforeseen weakness in the Company's markets, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, changes in the U.S. Government's interpretation of federal procurement rules and regulations, changes in spending due to policy changes in any new federal presidential administration, market acceptance of the Company's products, shortages in components, production delays due to performance quality issues with outsourced components, inability to fully realize the expected benefits from acquisitions and restructurings or delays in realizing such benefits, challenges in integrating acquired businesses and achieving anticipated synergies, changes to export regulations, increases in tax rates, changes to generally accepted accounting principles, difficulties in retaining key employees and customers, unanticipated costs under fixed-price service and system integration engagements, changes in the market for microcap stocks regardless of growth and value and various other factors beyond our control. You must carefully consider any such statement and should understand that many factors could cause actual results to differ from the Company's forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially. The Company does not assume the obligation to update any forward-looking statement. You should carefully evaluate such statements in light of factors described in the Company's filings with the SEC, especially on Forms 10-K, 10-Q and 8-K. In various filings the Company has identified important factors that could cause actual results to differ from expected or historic results. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider any such list to be a complete list of all potential risks or uncertainties. Contact: IR@ SOURCE: Optex Systems Holdings, Inc.
Miami Herald
a day ago
- Miami Herald
WanAware Survey Finds ITAM Confidence Gap is Costing Enterprises Time, Trust, and Millions in Missed Value
New survey of 600 enterprise leaders reveals growing investment in IT asset management, yet alarming visibility and alignment gaps persist across organizations. BOULDER, CO / ACCESS Newswire / August 12, 2025 / WanAware, an innovator in intelligent observability, today released a new report titled Closing the ITAM Confidence Gap: 2025 Survey Insights for IT Leaders, uncovering a stark divide in how IT teams and the broader business perceive the value and performance of ITAM systems. While IT managers express growing confidence in their tools, data, and ROI, most other departments remain unconvinced and often left in the dark. According to the survey of 600 professionals across IT, operations, and general management at multi-location enterprises, 95% of IT leaders say they trust their asset data, and 80% report growing investment in ITAM initiatives. But outside of IT, that confidence quickly erodes. Less than half of analysts feel good about ROI, and only 35% of other managers trust the accuracy of asset data. "This isn't just a perception problem, it's an operational one," said Jeff Collins, CEO of WanAware. "When confidence in IT asset data drops by half outside the IT department, it creates real risk, wasted spend, and delays that fly under the radar until it's too late." The report highlights how manual effort, fragmented tooling, and poor visibility continue to plague ITAM workflows. Nearly a quarter of IT teams still rely on spreadsheets and email threads to track assets. And even as IT leaders consolidate systems and adapt, the rest of the organization sees little progress. Non-IT respondents report fragmented tools, slow onboarding, and inconsistent data, undermining trust and making collaboration harder across finance, procurement, and compliance. The gap is more than frustrating, it's expensive. The survey estimates up to 25% of IT spend is wasted on "ghost assets" including devices and licenses that are no longer in use but remain on the books. These blind spots often fly under the radar, exposing companies to unnecessary tax, security, and compliance risk. When asked what would improve ITAM most, IT leaders weren't asking for bells and whistles. They pointed to real-time updates, automated responses to risky assets, and simplified tools that remove the burden of manual tracking. The goal is clear: fewer roadblocks, not more features. The disconnect also appears to be widening. Half of IT managers say missing assets cause significant disruption, compared to just 9% of their peers in other departments. And while IT teams report improved visibility since shifting to remote work, analysts and ops managers see no such benefit. These perception gaps fuel disengagement, workarounds, and wasted time, ultimately weakening the business case for ITAM investment. Still, WanAware believes alignment is possible. The report calls on IT leaders to take a more strategic role by proving the value of ITAM in business terms, integrating it with cybersecurity and service management tools, and making data and dashboards accessible to non-technical teams. "Asset management shouldn't be a gatekeeping function," said Collins. "It should be a command center. When asset data is real-time, trusted, and actionable, it becomes the foundation for smart operations, secure systems, and scalable growth." WanAware's own platform is built to solve exactly these issues, eliminating ghost assets with automated discovery, providing a shared real-time view across departments, and triggering policy-based remediation the moment an asset goes missing or risky. That combination of observability and automation is already helping enterprises close the confidence gap and regain control over sprawling, hybrid IT environments. Download the full 2025 ITAM Confidence Gap survey report here. Organizations can also now capitalize on a free 14-day trial of WanAware AIM to uncover gaps in their own environment and see real-time results: ### ABOUT WANAWARE: WanAware is an innovator in intelligent observability, dedicated to solving the most pressing challenges in IT performance, availability, and security monitoring. By leveraging advanced technologies, including AI and machine learning, WanAware delivers actionable insights that empower organizations to achieve operational excellence. For more information, visit MEDIA CONTACT: Nina Pfister, MAG PR at nina@ T: 781-929-5620. SOURCE: WanAware
Miami Herald
a day ago
- Miami Herald
MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin
Manuscript accepted for publication in Frontiers in Pharmacology, "Oral Administration of Ketamir-2, a Novel Ketamine Analog, Attenuates Neuropathic Pain in Rodent Models via Selective NMDA Antagonism" details Ketamir-2's superior performance in two validated neuropathic pain models and supports advancement to Phase 2a clinical trials by year-end 2025. MIAMI, FL / ACCESS Newswire / August 12, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced the acceptance of a second peer-reviewed manuscript describing its lead oral drug candidate, Ketamir-2, in Frontiers in Pharmacology. The newly accepted publication reports that Ketamir-2 outperformed ketamine, pregabalin, or gabapentin-depending on the comparator used-in restoring sensory function and reversing pain behaviors across two gold-standard rodent models of neuropathic pain. The findings build on MIRA's first publication characterizing Ketamir-2's clean pharmacology and favorable safety profile and align with the Company's plan to initiate a Phase 2a trial in neuropathic pain by year-end 2025. Market Opportunity Neuropathic pain represents a significant and underserved market across North America. Epidemiology suggests approximately 7-10% of the population experiences neuropathic pain; in North America, this equates to approximately 36-51 million people across the U.S., Canada, and Mexico. According to Precedence Research, the global neuropathic pain market is valued at approximately $7.97 billion in 2024 and is projected to reach $16.79 billion by 2034, growing at a compound annual growth rate (CAGR) of 7.73%. North America accounts for a significant share of this market, representing an estimated $3.7-3.9 billion annually today. The U.S. neuropathic pain market is estimated at $2.79 billion in 2024 and is projected to reach $5.92 billion by 2034, growing at a CAGR of 7.80% over the same period. Growth is expected to be driven by rising prevalence of diabetes, cancer survivorship, and aging-related nerve damage, underscoring the large and expanding commercial potential for novel treatments such as Ketamir-2. Ketamir-2's differentiated mechanism, oral bioavailability, and superior performance in gold-standard preclinical models position it as a potential next-generation, non-opioid treatment option in this multi-billion-dollar and rapidly growing market. Key Findings from the Publication Chung Model (sciatic nerve ligation in rats)Male rats: Ketamir-2 restored sensory thresholds toward baseline, while ketamine-tested as the comparator-showed no measurable rats: Ketamir-2 outperformed both pregabalin and gabapentin, delivering greater and more consistent restoration of normal sensory (PTX)-Induced Neuropathy in MiceGabapentin was the sole comparator in this chemotherapy-induced neuropathy model. Ketamir-2 produced more complete normalization of pain sensitivity in both male and female cohorts, while gabapentin provided only partial or inconsistent Across Genders and SpeciesDespite differences in baseline pain sensitivity between male and female animals, Ketamir-2 demonstrated clear and significant therapeutic benefit in every cohort tested. Mechanistic Differentiation Ketamir-2 is a new molecular entity that selectively binds to the PCP site of the NMDA receptor with low affinity and shows no significant interaction with over 40 other receptor systems, including serotonin, dopamine, and opioid receptors. This combination of selectivity, oral bioavailability, and demonstrated efficacy in gold-standard models suggests the potential for a differentiated, next-generation therapeutic option in neuropathic pain. "The acceptance of this second peer-reviewed publication is another important milestone for our Ketamir-2 program," said Erez Aminov, CEO of MIRA. "The data clearly demonstrate superior and more consistent pain relief compared to leading neuropathic pain drugs, within the specific models tested. This provides additional confidence as we advance Ketamir-2 toward Phase 2a clinical evaluation and continue to explore its potential in broader CNS applications." "The robust reversal of pain sensitivity observed in these well-validated preclinical models-whether compared to ketamine, pregabalin, or gabapentin-further supports Ketamir-2's potential as a differentiated, orally administered treatment for neuropathic pain," added Dr. Itzchak Angel, Chief Scientific Advisor. "Given the limited number of effective oral treatments for this indication, Ketamir-2's profile is especially compelling." Clinical Development Update Phase 1 Trial Progressing: The ongoing Phase 1 trial of Ketamir-2 in Israel is on schedule, with no safety concerns reported to date and the single ascending dose portion nearing 2a by Year-End: MIRA plans to submit a Phase 2a clinical trial protocol to the U.S. Food and Drug Administration (FDA) in Q4 2025 as an advanced development version to its active IND, with the goal of initiating the study in neuropathic pain by Beyond Neuropathic Pain: With its clean pharmacology and oral bioavailability, Ketamir-2 is also being explored for potential applications in depression, anxiety, post-traumatic stress disorder (PTSD), and as a topical formulation for localized pain conditions. The full publication will be available upon release at: About MIRA Pharmaceuticals, Inc. MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. Cautionary Note Regarding Forward-Looking Statements This press release and the statements of MIRA's management related thereto contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA's potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at and on MIRA's website at MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact:Helga Moyainfo@ 432-9792 SOURCE: MIRA Pharmaceuticals
